Aerts JMFG - Search Results

1

Gaucher disease protects against tuberculosis.

Fan J, Hale VL, Lelieveld LT, Whitworth LJ, Busch-Nentwich EM, Troll M, Edelstein PH, Cox TM, Roca FJ, Aerts JMFG, Ramakrishnan L. Fan J, et al. Among authors: aerts jmfg. Proc Natl Acad Sci U S A. 2023 Feb 14;120(7):e2217673120. doi: 10.1073/pnas.2217673120. Epub 2023 Feb 6. Proc Natl Acad Sci U S A. 2023. PMID: 36745788 Free PMC article.

2

An immunoelectron microscopic study of glucocerebrosidase in type 1 Gaucher's disease spleen.

Willemsen R, van Dongen JM, Aerts JM, Schram AW, Tager JM, Goudsmit R, Reuser AJ. Willemsen R, et al. Ultrastruct Pathol. 1988 Sep-Oct;12(5):471-8. doi: 10.3109/01913128809032232. Ultrastruct Pathol. 1988. PMID: 3194992

3

Plasma and metabolic abnormalities in Gaucher's disease.

Aerts JM, Hollak CE. Aerts JM, et al. Baillieres Clin Haematol. 1997 Dec;10(4):691-709. doi: 10.1016/s0950-3536(97)80034-0. Baillieres Clin Haematol. 1997. PMID: 9497858 Review.

4

Oligosaccharide excretion in adult Gaucher disease.

de Jong JG, Aerts JM, van Weely S, Hollak CE, van Pelt J, van Woerkom LM, Liebrand-van Sambeek ML, Wevers RA. de Jong JG, et al. J Inherit Metab Dis. 1998 Feb;21(1):49-59. doi: 10.1023/a:1005311430722. J Inherit Metab Dis. 1998. PMID: 9501269

5

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebícek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A. Cox T, et al. Lancet. 2000 Apr 29;355(9214):1481-5. doi: 10.1016/S0140-6736(00)02161-9. Lancet. 2000. PMID: 10801168 Clinical Trial.

6

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.

Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA, Butters TD, Cox TM, Lachmann RH, Hollak C, Aerts JM, Van Weely S, Hrebícek M, Moyses C, Gow I, Elstein D, Zimran A. Platt FM, et al. J Inherit Metab Dis. 2001 Apr;24(2):275-90. doi: 10.1023/a:1010335505357. J Inherit Metab Dis. 2001. PMID: 11405346 Review.

7

Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention.

Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, van Breemen MJ, van Meurs M, Boven LA, Laman JD, Moran MT, Cox TM, Aerts JM. Boot RG, et al. Blood. 2004 Jan 1;103(1):33-9. doi: 10.1182/blood-2003-05-1612. Epub 2003 Sep 11. Blood. 2004. PMID: 12969956 Free article.

8

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.

Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Miranda MC, Zimran A; Advisory Council to the European Working Group on Gaucher Disease. Cox TM, et al. J Inherit Metab Dis. 2003;26(6):513-26. doi: 10.1023/a:1025902113005. J Inherit Metab Dis. 2003. PMID: 14605497 Review.

9

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A. Elstein D, et al. J Inherit Metab Dis. 2004;27(6):757-66. doi: 10.1023/B:BOLI.0000045756.54006.17. J Inherit Metab Dis. 2004. PMID: 15505381 Clinical Trial.

10

Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.

Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, Cox TM. Deegan PB, et al. Blood Cells Mol Dis. 2005 Sep-Oct;35(2):259-67. doi: 10.1016/j.bcmd.2005.05.005. Blood Cells Mol Dis. 2005. PMID: 16125420

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

285 results

Search Page